Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer

  • Michela Garofalo,
  • Young-Jun Jeon,
  • Gerard J. Nuovo,
  • Justin Middleton,
  • Paola Secchiero,
  • Pooja Joshi,
  • Hansjuerg Alder,
  • Natalya Nazaryan,
  • Gianpiero Di Leva,
  • Giulia Romano,
  • Melissa Crawford,
  • Patrick Nana-Sinkam,
  • Carlo M. Croce
  • Article
  • Metrics
  • Comments
  • Media Coverage

After publication of this article [1] and initial correction [2], The Ohio State University informed PLOS ONE of the outcome of an investigation into this article. This investigation concluded that the article contains additional instances of text overlap that were not acknowledged in the previous correction [2].

We would like to acknowledge this and include the relevant references. It should be noted that no concerns have been raised regarding the originality of the work reported in the article, and that this has no bearing on the results and conclusions of the study.

In the Introduction section, there is some overlap in text with that from Bauman et al. (2007) [3] and Gallardo et al. (2009) [4].

The PLOS ONE Editors also identified instances where text from some of the authors’ own previously published work was reused in [1], as follows.

In the Results and Methods sections, there is some overlap in text with Acunzo et al. (2012) [5].

In the Methods section, there is some overlap in text with Garofalo et al. (2012) [6] and Garofalo et al. (2008) [7].

In the legend for Figure 1, there is some overlap in text with Garofalo et al. (2009) [8].

References

  1. 1. Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, et al. (2013) MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLOS ONE 8(6): e67581. https://doi.org/10.1371/journal.pone.0067581 pmid:23805317
  2. 2. Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, et al. (2015) Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLOS ONE 10(6): e0131729. https://doi.org/10.1371/journal.pone.0131729 pmid:26110899
  3. 3. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B et al. (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11): 903–1909. pmid:19736307
  4. 4. Bauman JE, Eaton KD and Martins RG (2007) Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations. Clin Cancer Res 13(15): 4632s–4636s. pmid:17671155
  5. 5. Acunzo M., Visone R., Romano G. et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31, 634–642 (2012). pmid:21706050
  6. 6. Garofalo M., Romano G., Di Leva G. et al. EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18, 74–82 (2012). pmid:22157681
  7. 7. Garofalo M., Quintavalle C., Di Leva G. et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27, 3845–3855 (2008). pmid:18246122
  8. 8. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6): 498–509. pmid:19962668

Citation: Garofalo M, Jeon Y-J, Nuovo GJ, Middleton J, Secchiero P, Joshi P, et al. (2022) Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS ONE 17(4): e0267628. https://doi.org/10.1371/journal.pone.0267628

Published: April 20, 2022

Copyright: © 2022 Garofalo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.